Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 48 entries
Sorted by: Best Match Show Resources per page
Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.

Oncotarget

Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A.
PMID: 29050204
Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19.

The permanent defects in bone growth observed in preclinical studies of hedgehog (Hh) pathway inhibitors were not substantiated in early phase clinical studies of vismodegib in children. Consequently, vismodegib advanced into pediatric trials for malignancies suspected of being driven...

Cite
Robinson GW, Kaste SC, Chemaitilly W, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8(41):69295-69302doi: 10.18632/oncotarget.20619.
Robinson, G. W., Kaste, S. C., Chemaitilly, W., Bowers, D. C., Laughton, S., Smith, A., Gottardo, N. G., Partap, S., Bendel, A., Wright, K. D., Orr, B. A., Warner, W. C., Onar-Thomas, A., & Gajjar, A. (2017). Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget, 8(41), 69295-69302. https://doi.org/10.18632/oncotarget.20619
Robinson, Giles W, et al. "Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor." Oncotarget vol. 8,41 (2017): 69295-69302. doi: https://doi.org/10.18632/oncotarget.20619
Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19. PMID: 29050204; PMCID: PMC5642479.
Copy Download .nbib Format: NLM
Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests.

Hepatology communications

Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ.
PMID: 30859146
Hepatol Commun. 2019 Jan 23;3(3):325-339. doi: 10.1002/hep4.1310. eCollection 2019 Mar.

Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study assessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program efficiency of testing strategies....

Cite
Chemaitelly H, Mahmud S, Kouyoumjian SP, et al. Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests. Hepatol Commun. 2019;3(3):325-339doi: 10.1002/hep4.1310.
Chemaitelly, H., Mahmud, S., Kouyoumjian, S. P., Al-Kanaani, Z., Hermez, J. G., & Abu-Raddad, L. J. (2019). Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests. Hepatology communications, 3(3), 325-339. https://doi.org/10.1002/hep4.1310
Chemaitelly, Hiam, et al. "Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests." Hepatology communications vol. 3,3 (2019): 325-339. doi: https://doi.org/10.1002/hep4.1310
Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests. Hepatol Commun. 2019 Jan 23;3(3):325-339. doi: 10.1002/hep4.1310. eCollection 2019 Mar. PMID: 30859146; PMCID: PMC6396361.
Copy Download .nbib Format: NLM
Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa.

Hepatology communications

Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ.
PMID: 32258952
Hepatol Commun. 2020 Feb 28;4(4):577-587. doi: 10.1002/hep4.1491. eCollection 2020 Apr.

We investigated hepatitis C virus (HCV) epidemiology in populations with liver-related diseases (LRDs) in the Middle East and North Africa. The data source was standardized databases of HCV measures populated through systematic reviews. Random-effects meta-analyses and meta-regressions were performed,...

Cite
Mahmud S, Chemaitelly H, Al Kanaani Z, et al. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4(4):577-587doi: 10.1002/hep4.1491.
Mahmud, S., Chemaitelly, H., Al Kanaani, Z., Kouyoumjian, S. P., & Abu-Raddad, L. J. (2020). Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatology communications, 4(4), 577-587. https://doi.org/10.1002/hep4.1491
Mahmud, Sarwat, et al. "Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa." Hepatology communications vol. 4,4 (2020): 577-587. doi: https://doi.org/10.1002/hep4.1491
Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020 Feb 28;4(4):577-587. doi: 10.1002/hep4.1491. eCollection 2020 Apr. PMID: 32258952; PMCID: PMC7109336.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection rates in air passengers arriving in Qatar.

Journal of travel medicine

Butt AA, Al-Halabi AM, Ghazouani H, Rhouma MBH, Ayoub HH, Masoodi NA, Borham AM, Hommos AA, Bertollini R, Chemaitelly H, Abu Raddad LJ, Abou-Samra AB.
PMID: 34622294
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab163.

No abstract available.

Cite
Butt AA, Al-Halabi AM, Ghazouani H, et al. SARS-CoV-2 infection rates in air passengers arriving in Qatar. J Travel Med. 2021;28(8)doi: 10.1093/jtm/taab163.
Butt, A. A., Al-Halabi, A. M., Ghazouani, H., Rhouma, M. B. H., Ayoub, H. H., Masoodi, N. A., Borham, A. M., Hommos, A. A., Bertollini, R., Chemaitelly, H., Abu Raddad, L. J., & Abou-Samra, A. B. (2021). SARS-CoV-2 infection rates in air passengers arriving in Qatar. Journal of travel medicine, 28(8), . https://doi.org/10.1093/jtm/taab163
Butt, Adeel A, et al. "SARS-CoV-2 infection rates in air passengers arriving in Qatar." Journal of travel medicine vol. 28,8 (2021). doi: https://doi.org/10.1093/jtm/taab163
Butt AA, Al-Halabi AM, Ghazouani H, Rhouma MBH, Ayoub HH, Masoodi NA, Borham AM, Hommos AA, Bertollini R, Chemaitelly H, Abu Raddad LJ, Abou-Samra AB. SARS-CoV-2 infection rates in air passengers arriving in Qatar. J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab163. PMID: 34622294; PMCID: PMC8524449.
Copy Download .nbib Format: NLM
Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020.

Global epidemiology

Ayoub HH, Mumtaz GR, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad LJ.
PMID: 34841244
Glob Epidemiol. 2021 Nov;3:100068. doi: 10.1016/j.gloepi.2021.100068. Epub 2021 Nov 23.

We aimed to estimate, albeit crudely and provisionally, national, regional, and global proportions of respective populations that have been infected with SARS-CoV-2 in the first year after the introduction of this virus into human circulation, and to assess infection...

Cite
Ayoub HH, Mumtaz GR, Seedat S, et al. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021;3:100068doi: 10.1016/j.gloepi.2021.100068.
Ayoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H., & Abu-Raddad, L. J. (2021). Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Global epidemiology, 3100068. https://doi.org/10.1016/j.gloepi.2021.100068
Ayoub, Houssein H, et al. "Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020." Global epidemiology vol. 3 (2021): 100068. doi: https://doi.org/10.1016/j.gloepi.2021.100068
Ayoub HH, Mumtaz GR, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad LJ. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021 Nov;3:100068. doi: 10.1016/j.gloepi.2021.100068. Epub 2021 Nov 23. PMID: 34841244; PMCID: PMC8609676.
Copy Download .nbib Format: NLM
Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Pituitary

Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, Chemaitilly W, Higham CE, Johannsson G, Yuen KCJ.
PMID: 34304361
Pituitary. 2021 Oct;24(5):810-827. doi: 10.1007/s11102-021-01173-0. Epub 2021 Jul 25.

Individuals surviving cancer and brain tumors may experience growth hormone (GH) deficiency as a result of tumor growth, surgical resection and/or radiotherapy involving the hypothalamic-pituitary region. Given the pro-mitogenic and anti-apoptotic properties of GH and insulin-like growth factor-I, the...

Cite
Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, et al. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary. 2021;24(5):810-827doi: 10.1007/s11102-021-01173-0.
Boguszewski, M. C. S., Cardoso-Demartini, A. A., Boguszewski, C. L., Chemaitilly, W., Higham, C. E., Johannsson, G., & Yuen, K. C. J. (2021). Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary, 24(5), 810-827. https://doi.org/10.1007/s11102-021-01173-0
Boguszewski, Margaret C S, et al. "Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice." Pituitary vol. 24,5 (2021): 810-827. doi: https://doi.org/10.1007/s11102-021-01173-0
Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, Chemaitilly W, Higham CE, Johannsson G, Yuen KCJ. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary. 2021 Oct;24(5):810-827. doi: 10.1007/s11102-021-01173-0. Epub 2021 Jul 25. PMID: 34304361; PMCID: PMC8416866.
Copy Download .nbib Format: NLM
Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wilson CL, Liu W, Chemaitilly W, Howell CR, Srivastava DK, Howell RM, Hudson MM, Robison LL, Ness KK.
PMID: 32796078
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1750-1758. doi: 10.1158/1055-9965.EPI-19-1321. Epub 2020 Aug 13.

BACKGROUND: We aimed to characterize body composition, metabolic impairments, and physical performance among survivors of pediatric abdominal and pelvic solid tumors.METHODS: Participants included 431 survivors of abdominal or pelvic tumors [median attained age = 29.9 (range: 18.7-55.1) years]. Relative...

Cite
Wilson CL, Liu W, Chemaitilly W, et al. Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1750-1758doi: 10.1158/1055-9965.EPI-19-1321.
Wilson, C. L., Liu, W., Chemaitilly, W., Howell, C. R., Srivastava, D. K., Howell, R. M., Hudson, M. M., Robison, L. L., & Ness, K. K. (2020). Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1750-1758. https://doi.org/10.1158/1055-9965.EPI-19-1321
Wilson, Carmen L, et al. "Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1750-1758. doi: https://doi.org/10.1158/1055-9965.EPI-19-1321
Wilson CL, Liu W, Chemaitilly W, Howell CR, Srivastava DK, Howell RM, Hudson MM, Robison LL, Ness KK. Body Composition, Metabolic Health, and Functional Impairment among Adults Treated for Abdominal and Pelvic Tumors during Childhood. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1750-1758. doi: 10.1158/1055-9965.EPI-19-1321. Epub 2020 Aug 13. PMID: 32796078; PMCID: PMC7721344.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection rates in arriving air Travelers in Qatar.

Journal of travel medicine

Butt AA, Al-Halabi AM, Ghazouani H, Rhouma MBH, Ayoub HH, Masoodi NA, Borham AM, Hommos AA, Bertollini R, Chemaitelly H, Abu Raddad LJ, Abou-Samra AB.
PMID: 34622294
J Travel Med. 2021 Oct 08; doi: 10.1093/jtm/taab163. Epub 2021 Oct 08.

Among 352 174 airline travelers entering Qatar, 8236 (2.34%) tested positive on or within the first seven days of arrival, with 3789 (1.08%) testing positive at the time of arrival and the remaining 4447 (1.26%) testing negative at arrival...

Cite
Butt AA, Al-Halabi AM, Ghazouani H, et al. SARS-CoV-2 infection rates in arriving air Travelers in Qatar. J Travel Med. 2021;doi: 10.1093/jtm/taab163.
Butt, A. A., Al-Halabi, A. M., Ghazouani, H., Rhouma, M. B. H., Ayoub, H. H., Masoodi, N. A., Borham, A. M., Hommos, A. A., Bertollini, R., Chemaitelly, H., Abu Raddad, L. J., & Abou-Samra, A. B. (2021). SARS-CoV-2 infection rates in arriving air Travelers in Qatar. Journal of travel medicine, . https://doi.org/10.1093/jtm/taab163
Butt, Adeel A, et al. "SARS-CoV-2 infection rates in arriving air Travelers in Qatar." Journal of travel medicine vol. (2021). doi: https://doi.org/10.1093/jtm/taab163
Butt AA, Al-Halabi AM, Ghazouani H, Rhouma MBH, Ayoub HH, Masoodi NA, Borham AM, Hommos AA, Bertollini R, Chemaitelly H, Abu Raddad LJ, Abou-Samra AB. SARS-CoV-2 infection rates in arriving air Travelers in Qatar. J Travel Med. 2021 Oct 08; doi: 10.1093/jtm/taab163. Epub 2021 Oct 08. PMID: 34622294; PMCID: PMC8524449.
Copy Download .nbib Format: NLM
Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020.

Global epidemiology

Ayoub HH, Mumtaz GR, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad LJ.
PMID: 34841244
Glob Epidemiol. 2021 Nov;3:100068. doi: 10.1016/j.gloepi.2021.100068. Epub 2021 Nov 23.

We aimed to estimate, albeit crudely and provisionally, national, regional, and global proportions of respective populations that have been infected with SARS-CoV-2 in the first year after the introduction of this virus into human circulation, and to assess infection...

Cite
Ayoub HH, Mumtaz GR, Seedat S, et al. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021;3:100068doi: 10.1016/j.gloepi.2021.100068.
Ayoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H., & Abu-Raddad, L. J. (2021). Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Global epidemiology, 3100068. https://doi.org/10.1016/j.gloepi.2021.100068
Ayoub, Houssein H, et al. "Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020." Global epidemiology vol. 3 (2021): 100068. doi: https://doi.org/10.1016/j.gloepi.2021.100068
Ayoub HH, Mumtaz GR, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad LJ. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021 Nov;3:100068. doi: 10.1016/j.gloepi.2021.100068. Epub 2021 Nov 23. PMID: 34841244; PMCID: PMC8609676.
Copy Download .nbib Format: NLM
Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant.

The New England journal of medicine

Chemaitelly H, Bertollini R, Abu-Raddad LJ.
PMID: 34910864
N Engl J Med. 2021 Dec 30;385(27):2585-2586. doi: 10.1056/NEJMc2110300. Epub 2021 Dec 15.

No abstract available.

Cite
Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. N Engl J Med. 2021;385(27):2585-2586doi: 10.1056/NEJMc2110300.
Chemaitelly, H., Bertollini, R., Abu-Raddad, L. J. (2021). Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. The New England journal of medicine, 385(27), 2585-2586. https://doi.org/10.1056/NEJMc2110300
Chemaitelly, Hiam, et al. "Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant." The New England journal of medicine vol. 385,27 (2021): 2585-2586. doi: https://doi.org/10.1056/NEJMc2110300
Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. N Engl J Med. 2021 Dec 30;385(27):2585-2586. doi: 10.1056/NEJMc2110300. Epub 2021 Dec 15. PMID: 34910864; PMCID: PMC8693689.
Copy Download .nbib Format: NLM
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

Nature medicine

Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ.
PMID: 34728831
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 02.

With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against...

Cite
Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136-2143doi: 10.1038/s41591-021-01583-4.
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., Butt, A. A., Al-Thani, M. H., Al Khal, A., Bertollini, R., & Abu-Raddad, L. J. (2021). BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature medicine, 27(12), 2136-2143. https://doi.org/10.1038/s41591-021-01583-4
Tang, Patrick, et al. "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar." Nature medicine vol. 27,12 (2021): 2136-2143. doi: https://doi.org/10.1038/s41591-021-01583-4
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 02. PMID: 34728831.
Copy Download .nbib Format: NLM
Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.

PLoS medicine

Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Tang P, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R.
PMID: 34914711
PLoS Med. 2021 Dec 16;18(12):e1003879. doi: 10.1371/journal.pmed.1003879. Epub 2021 Dec 16.

BACKGROUND: The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study's objective was to describe the introduction and expansion of this variant in Qatar and to estimate the efficacy of natural infection against reinfection with...

Cite
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med. 2021;18(12):e1003879doi: 10.1371/journal.pmed.1003879.
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., Al Kuwari, E., Butt, A. A., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Yassine, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, M. H., Al Khal, A., & Bertollini, R. (2021). Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS medicine, 18(12), e1003879. https://doi.org/10.1371/journal.pmed.1003879
Abu-Raddad, Laith J, et al. "Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study." PLoS medicine vol. 18,12 (2021): e1003879. doi: https://doi.org/10.1371/journal.pmed.1003879
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Tang P, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med. 2021 Dec 16;18(12):e1003879. doi: 10.1371/journal.pmed.1003879. Epub 2021 Dec 16. PMID: 34914711.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 48 entries